EXOZYMES INC.
EXOZ evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for EXOZ—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EXOZ
ExoZymes Inc. is a pre-revenue biotechnology company developing cell-free enzymatic platforms for industrial applications, funded by grants and a recent IPO, but faces significant cash runway constraints.
Key risk: Cash runway insufficient
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for EXOZYMES INC..
ExoZymes Inc. is a pre-revenue biotechnology company developing cell-free enzymatic platforms for industrial applications, funded by grants and a recent IPO, but faces significant cash runway constraints.
- Cash and equivalents of $5.7M as of 2026-06-30, with a net loss of -$2.9M for the quarter [sec].
- Working capital declined from $9.5M at end of 2024 to $507,586 as of March 31, 2026, and management states existing capital is insufficient for 12 months of operations [sec_mda · as of 2026-05-14].
- The company completed an IPO in 2024, raising net proceeds of $15.2M, and concurrently issued warrants exercisable at $8.00 per share [sec_mda · as of 2025-03-31].
- Awarded a $3M share of a $9.2M NSF grant (CFIRE program) on July 1, 2025, and a $283,805 NIH BioClick grant in March 2025 [sec_mda · as of 2026-08-13].
- No committed sources of additional financing; the company may seek equity sales, debt, or licensing to fund operations [sec_mda · as of 2026-05-14].
What works
- Non-dilutive grant funding: ExoZymes has secured multiple government grants, including a $3M NSF award and an NIH BioClick grant, supporting R&D without diluting equity [sec_mda · as of 2026-08-13].
- IPO capital base: The 2024 IPO provided $15.2M in net proceeds, enabling initial investment in production capabilities, staffing, and R&D [sec_mda · as of 2025-03-31].
- Focus on cell-free platform: The company's proprietary cell-free enzymatic platform targets scalable, real-world industrial applications, a differentiated approach in synthetic biology [sec_mda · as of 2026-08-13].
What to weigh
- Cash runway risk: As of March 31, 2026, working capital of $507,586 is insufficient to fund operations for 12 months, and the company has no committed financing sources [sec_mda · as of 2026-05-14].
- Pre-revenue status: The company has not reported product revenue; operating cash burn was $8.5M in 2024 and continues, with net loss of $2.9M in the latest quarter [sec_mda · as of 2025-03-31][sec].
- Dependence on external funding: ExoZymes relies on grants and potential future equity/debt offerings, with no assurance of obtaining additional capital on reasonable terms [sec_mda · as of 2026-05-14].
- Limited revenue diversification: The company's only disclosed funding sources are grants and IPO proceeds; no commercial partnerships or product sales are mentioned [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Working capital insufficient for 12 months
“Given its current operating cash burn, the Company's existing working capital is not sufficient to fund operations for a full twelve-month period, determined as of March 31, 2026.”
SEC MD&A · May 14, 2026
NSF grant award of $3M
“On July 1, 2025, the Company was awarded a key industrial partnership, with a $3 million share of a $9.2 million grant.”
SEC MD&A · August 13, 2026
IPO net proceeds of $15.2M
“The net proceeds for the initial public offering with the overallotment were $15,206,543 as of the date of this report.”
SEC MD&A · March 31, 2025
Risks & what to watch (4)›
Key risks
- Cash runway insufficient — Working capital of $507,586 as of March 31, 2026, is not enough for 12 months of operations [sec_mda · as of 2026-05-14].
- No committed financing — The company has no committed sources of additional funding and may not secure capital on reasonable terms [sec_mda · as of 2026-05-14].
- Pre-revenue and net losses — ExoZymes has no product revenue and reported a net loss of $2.9M in the latest quarter [sec].
- Dependence on grants — Operations rely on government grants, which are not guaranteed and may be delayed or reduced [sec_mda · as of 2026-08-13].
What to watch
- Ability to secure additional financing (equity, debt, or grants) to extend cash runway beyond mid-2026 [sec_mda · as of 2026-05-14].
- Progress on NSF and NIH grant-funded projects, particularly the CFIRE cell-free systems program [sec_mda · as of 2026-08-13].
- Any commercial partnerships or licensing deals that could generate revenue or non-dilutive funding [sec_mda · as of 2026-05-14].
- Cash burn rate and working capital updates in future quarterly filings [sec].
Sources: SEC MD&A · Generated August 14, 2026 · How we verify sources →
Run EXOZYMES INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available EXOZYMES INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
10.6 months
D/E 1.18 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
0 buys · 2 sells (180d)
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
5
Total value held
$628K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 44,380 | $333K |
| geode capital management, llc | 21,891 | $164K |
| vanguard fiduciary trust co | 9,426 | $71K |
| blackrock, inc. | 6,797 | $51K |
| morgan stanley | 1,250 | $9K |
Short Interest
as of Apr 20, 2026- % of float
- 0.3%
- Days to cover
- 2.8
- Shares short
- 10,666
- Daily short volume (Jun 8, 2026)
- 35.5%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EXOZ short interestGovernance
Frequently asked questions
What is the AI investment thesis for EXOZYMES INC.?
ExoZymes Inc. is a pre-revenue biotechnology company developing cell-free enzymatic platforms for industrial applications, funded by grants and a recent IPO, but faces significant cash runway constraints.
What is EXOZYMES INC.'s lead drug candidate?
EXOZYMES INC.'s most advanced tracked candidate is isobutanol (Preclinical) for Sustainable Aviation Fuel (SAF) and other sustainable biofuels and industrial chemical applications.
Who is the CEO of EXOZYMES INC.?
Mr. Michael Heltzen is the chief executive officer of EXOZYMES INC. (EXOZ).
Where is EXOZYMES INC. headquartered?
EXOZYMES INC. (EXOZ) is headquartered in Monrovia, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.